Brighton and Sussex Medical School

BACKGROUND: Whether the treatment of patients with hypertension who are 80 years of age or older is beneficial is unclear. It has been suggested that antihypertensive therapy may reduce the risk of stroke, despite possibly increasing the risk of death. METHODS: We randomly assigned 3845 patients from Europe, China, Australasia, and Tunisia who were 80 years of age or older and had a sustained systolic blood pressure of 160 mm Hg or more to receive either the diuretic indapamide (sustained release, 1.5 mg) or matching placebo. The angiotensin-converting-enzyme inhibitor perindopril (2 or 4 mg), or matching placebo, was added if necessary to achieve the target blood pressure of 150/80 mm Hg. The primary end point was fatal or nonfatal stroke. RESULTS: The active-treatment group (1933 patients) and the placebo group (1912 patients) were well matched (mean age, 83.6 years; mean blood pressure while sitting, 173.0/90.8 mm Hg); 11.8% had a history of cardiovascular disease. Median follow-up was 1.8 years. At 2 years, the mean blood pressure while sitting was 15.0/6.1 mm Hg lower in the active-treatment group than in the placebo group. In an intention-to-treat analysis, active treatment was associated with a 30% reduction in the rate of fatal or nonfatal stroke (95% confidence interval [CI], -1 to 51; P=0.06), a 39% reduction in the rate of death from stroke (95% CI, 1 to 62; P=0.05), a 21% reduction in the rate of death from any cause (95% CI, 4 to 35; P=0.02), a 23% reduction in the rate of death from cardiovascular causes (95% CI, -1 to 40; P=0.06), and a 64% reduction in the rate of heart failure (95% CI, 42 to 78; P<0.001). Fewer serious adverse events were reported in the active-treatment group (358, vs. 448 in the placebo group; P=0.001). CONCLUSIONS: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial. (ClinicalTrials.gov number, NCT00122811 [ClinicalTrials.gov].).

IMPORTANCE: Cancer is among the leading causes of death worldwide. Current estimates of cancer burden in individual countries and regions are necessary to inform local cancer control strategies. OBJECTIVE: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex from 1990 to 2013. EVIDENCE REVIEW: The general methodology of the Global Burden of Disease (GBD) 2013 study was used. Cancer registries were the source for cancer incidence data as well as mortality incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal autopsy studies, and other sources. The MI ratios were used to transform incidence data to mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying prevalence estimates with disability weights, which were derived from population-based surveys; YLLs were computed by multiplying the number of estimated cancer deaths at each age with a reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs. FINDINGS: In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries. CONCLUSIONS AND RELEVANCE: Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn's and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn's disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn's disease, including patients, their families and friends.

0

BACKGROUND: Sentinel lymph node biopsy in women with operable breast cancer is routinely used in some countries for staging the axilla despite limited data from randomized trials on morbidity and mortality outcomes. We conducted a multicenter randomized trial to compare quality-of-life outcomes between patients with clinically node-negative invasive breast cancer who received sentinel lymph node biopsy and patients who received standard axillary treatment. METHODS: The primary outcome measures were arm and shoulder morbidity and quality of life. From November 1999 to October 2003, 1031 patients were randomly assigned to undergo sentinel lymph node biopsy (n = 515) or standard axillary surgery (n = 516). Patients with sentinel lymph node metastases proceeded to delayed axillary clearance or received axillary radiotherapy (depending on the protocol at the treating institution). Intention-to-treat analyses of data at 1, 3, 6, and 12 months after surgery are presented. All statistical tests were two-sided. RESULTS: The relative risks of any lymphedema and sensory loss for the sentinel lymph node biopsy group compared with the standard axillary treatment group at 12 months were 0.37 (95% confidence interval [CI] = 0.23 to 0.60; absolute rates: 5% versus 13%) and 0.37 (95% CI = 0.27 to 0.50; absolute rates: 11% versus 31%), respectively. Drain usage, length of hospital stay, and time to resumption of normal day-to-day activities after surgery were statistically significantly lower in the sentinel lymph node biopsy group (all P < .001), and axillary operative time was reduced (P = .055). Overall patient-recorded quality of life and arm functioning scores were statistically significantly better in the sentinel lymph node biopsy group throughout (all P < or = .003). These benefits were seen with no increase in anxiety levels in the sentinel lymph node biopsy group (P > .05). CONCLUSION: Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.

Interoception refers to the sensing of internal bodily changes. Interoception interacts with cognition and emotion, making measurement of individual differences in interoceptive ability broadly relevant to neuropsychology. However, inconsistency in how interoception is defined and quantified led to a three-dimensional model. Here, we provide empirical support for dissociation between dimensions of: (1) interoceptive accuracy (performance on objective behavioural tests of heartbeat detection), (2) interoceptive sensibility (self-evaluated assessment of subjective interoception, gauged using interviews/questionnaires) and (3) interoceptive awareness (metacognitive awareness of interoceptive accuracy, e.g. confidence-accuracy correspondence). In a normative sample (N=80), all three dimensions were distinct and dissociable. Interoceptive accuracy was only partly predicted by interoceptive awareness and interoceptive sensibility. Significant correspondence between dimensions emerged only within the sub-group of individuals with greatest interoceptive accuracy. These findings set the context for defining how the relative balance of accuracy, sensibility and awareness dimensions explain cognitive, emotional and clinical associations of interoceptive ability.

Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC.&#13;\n&#13;\nPatients and methods: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs.&#13;\n&#13;\nResults: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P &lt; 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P &lt; 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P &lt; 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III.&#13;\n&#13;\nConclusions: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.&#13;\n&#13;\nKeywords: RCB; TILs; TNBC; neoadjuvant; prognosis.

Neutrophils play a key role in the elimination of pathogens. They are remarkably short-lived with a circulating half life of 6-8h and hence are produced at a rate of 5x10(10)-10x10(10) cells/day. Tight regulation of these cells is vital because they have significant histotoxic capacity and are widely implicated in tissue injury. This review outlines our current understanding of how neutrophils are released from the bone marrow; in particular, the role of the CXC chemokine receptor 4/stromal-derived factor 1 axis, the relative size and role of the freely circulating and marginated (i.e. slowly transiting) pools within the vascular compartment, and the events that result in the uptake and removal of circulating neutrophils. We also review current understanding of how systemic stress and inflammation affect this finely balanced system.

The relationship between income distribution and mortality is explored using data from published sources. Specifically the author attempts to investigate the cross sectional relation between income distribution and mortality and its possible interactions with gross national product per head and to assess whether changes in income distribution over time are related to changes in mortality in developed countries. He concludes that there is clear evidence of a strong relation between a societys income distribution and the average life expectancy of its population. (EXCERPT)

Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years and a 5-year survival of only ∼25% [2.Cardoso F. Spence D. Mertz S. et al.Global analysis of advanced/metastatic breast cancer: decade report (2005–2015).Breast. 2018; 39: 131-138Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar, 3.N Howlader, AM Noone, M Krapcho et al (eds). SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.Google Scholar]. The MBC Decade Report [2.Cardoso F. Spence D. Mertz S. et al.Global analysis of advanced/metastatic breast cancer: decade report (2005–2015).Breast. 2018; 39: 131-138Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive L. survival in metastatic breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar, et of on the of with metastatic breast PubMed Scopus Google Scholar, et and overall survival of with advanced breast the Full Text Full Text PDF PubMed Scopus Google Scholar]. The survival in an with to the and in to to and survival of and metastatic breast cancer Cancer 2018; PubMed Scopus Google Scholar, D. et for breast cancer metastatic and the Cancer Cancer PubMed Scopus Google Scholar]. The decade has an improvement in the of for of the the for the of breast cancer More and in to to a The of and the of data analysis to to the the to the and of of and of to the the of the for The International Consensus for in on November and the of for the of based on the and to in with the due to to The a and and of Breast Cancer of for International Cancer International and of of in the The the of of Cancer and with the of the Cancer and the for the The the and with the of of the and the of to et of Full Text Full Text PDF PubMed Scopus Google and for et of Full Text Full Text PDF PubMed Scopus Google Scholar] to for the the a of on the of based on data and the to for and on and of and the of to on with with a of the due to of in a to in the the the data to an in the of the The to of and the and on the and and to that only and a of the that and in of the of the for PubMed Scopus Google of of the and of with the that a of of and with and and studies and of the of to a for a on the 2 years of of for on on the 2 of for on disease metastatic disease with and of metastatic to and in the for a with with to for of the to for in the of for of and the a in on a to of of in the of an for with the of for with a of and in the of to the of of and the of with in a advanced breast of in with the of human epidermal growth factor of disease in a advanced breast of in with the of human epidermal growth factor of disease the to and the of a in the of with receptor ABC. in the for the of to an [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text Full Text PDF PubMed Scopus (252) Google Scholar, F. Costa A. et International Consensus Guidelines for Advanced Breast Cancer publication Google Scholar]. The for due to and a a and with The that an in of the of in the of The to with of and and the and of and a to of the of with an a the of the the of the some data regarding the of the with that in terms of and S. A. et with in with advanced breast 23: PubMed Scopus Google Scholar, et in with breast Cancer PubMed Scopus Google Scholar] in of and and a with for of of in a to and the of of and a of The to the of the a and of the of that incurable treatable, and that some with for of years in some in the and and information and information disease and the to in the to and to cancer and to the of and cancer a and and of information in a to in and to with to the of cancer and to cancer to the and to Breast in Breast a and a in the of and and an quality the breast cancer and to and and for and to the of for to the of disease and of a of and to in and to to the and the of of for of in in of on and and that both in the and to to of and of More to that data to of in of in a and the to for in and for to of a data on and of the the of in of life and the of the the to the of a and in with the of both for of breast cancer and for growth the the and the the survival in with of of the of to and to disease and and life to for and and in the and to to for the to with and in to and with a the to breast with breast an a of the of the on with with of and the of The information the of the disease and the of breast of the some a and of in to of with in an to a and that of advanced breast of of in with the for for and of for of of Cancer and of of quality of in a advanced breast of of in with the for for and of for of of Cancer and of of quality of The of data the in some the to the a and to the to and on and that to a on the of that of terms of the some to the Guidelines to and the of the and to the of the of with the et a of the for with to Full Text Full Text PDF PubMed Scopus Google the the of both for of breast cancer and for growth only that the and the the and in to to a and to with breast the of the to the for cancer for advanced cancer to a the for the of Breast has been and with the for the decade F. L. Costa A. et Breast Cancer on breast Full Text Full Text PDF PubMed Scopus Google Scholar]. some in of disease with to for and in has the to the on of for of the of a for a and with the and regarding the of the disease and the of the with the and et and Guidelines for and Full Text Full Text PDF PubMed Scopus Google Scholar, of for and in a Full Text Full Text PDF PubMed Scopus Google Scholar, et for with cancer: of PubMed Scopus Google Scholar, for and PubMed Scopus Google Scholar]. the of in the survival with and to Although of in to for that for and in terms of both and for in the for and of Cancer and of Cancer and that with to to of and of More to that data to for in and the of an the of and Breast Cancer and disease for a and and and of and in to with with metastatic of for an to to in with metastatic in to a in of to for to for on the of the the and of metastatic and of of in with in a of the and of a metastatic to for the and in the metastatic on the metastatic to with the the of in the metastatic the for a to the of in of the of the in with breast cancer has been with of with the of the of with in to the some studies that only with the to of the in with the of the and of with for with disease metastatic disease that to and a with for and and and of for a and in the and of the the to to the of and on the the for ABC. for with for disease the of for in and for and and a for the with and with for of and and a for the the metastatic with an and a and the and The and and in the a has been of in the that has been and that in has been of a for The and and to with of and the of to with the with for only a in and in The of for on only an in in and for advanced breast of in with the of human epidermal growth factor of OS, overall disease quality of breast in a for advanced breast of in with the of human epidermal growth factor of OS, overall disease quality of breast the for in the of of in that with and in the with and with to for of both and and for with the and with and for on the of and on a the only for the a on the and of the the of an for and with with and of a to an in to a improvement in median with an and of the for and with with and the of in the studies and for to that with of a to in to improvement in median improvement in and of the a for and with and and of to an a for some and with with and to of The to the with of and with and of in with due to the of in the of on the advanced the of the and and with with and and of the of with and with and on that to the of a to and of the for in of a and for in improvement in both and with in and in a with a analysis that the to to on to some with to and has a survival and a to a has been in advanced breast of in with the for of of human epidermal growth factor of of OS, overall disease quality of in a advanced breast of in with the for of of human epidermal growth factor of of OS, overall disease quality of of the to in of the advances in the in and in with the for in the of only with for in to in due to and that that for the of in F. A. in Full Text Full Text PDF PubMed Scopus Google regarding and of the of with of the of in with F. Costa A. Norton L. et International for advanced breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar]. the to the that to both and and for and for The of in the of in the and on with on for to for the of The on and the due to the with and only of the the publication of the et for advanced breast cancer an Full Text Full Text PDF PubMed Scopus Google for an and The in the The 2 years the of and the and the the that regarding the of in of the the of and a to with and with for the and on the et of Full Text Full Text PDF PubMed Scopus Google Scholar] to in both and and some and the to The of in the has been with a in et in with of advanced breast cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar, et and in advanced breast PubMed Scopus Google Scholar, et for advanced breast PubMed Scopus Google Scholar, et a of in advanced breast cancer Google Scholar, D. et with and a in with advanced breast cancer: the 2018; Scholar, A. et for with advanced breast Scholar, A. et a of a in of with metastatic breast cancer Google a with with the in has been with an improvement in et of on quality of the 2018; Full Text Full Text PDF PubMed Scopus Google Scholar, S. et quality of life of with human epidermal growth factor receptor advanced breast cancer (ABC) with Google in D. et with and a in with advanced breast cancer: the 2018; Scholar]. in that disease with of both in the and the S. et of disease on to of quality of life in breast cancer in the Full Text PDF Google Scholar]. the the of a in the an of the has been with a survival et for of metastatic breast cancer that on analysis of the Full Text Full Text PDF PubMed Scopus Google Scholar, et in with in with advanced breast cancer PubMed Scopus Google Scholar] and an improvement S. et of life with in metastatic breast cancer: the Full Text Full Text PDF PubMed Scopus Google Scholar, S. et in with in with advanced breast cancer: analysis a PubMed Scopus Google and some in the the with and with with and for with has et a of a and a in with metastatic breast Cancer 23: PubMed Scopus Google Scholar, S. A. analysis and disease in a 2 of a in with metastatic breast cancer (MBC) Scholar] for the D. et for the of to receptor breast Google Scholar]. of an with has a a et for human epidermal growth factor advanced breast cancer: overall survival 2014; Full Text Full Text PDF PubMed Scopus Google Scholar, et of in with in with human epidermal growth factor receptor metastatic breast cancer with to a PubMed Scopus Google Scholar] in the recently, in the et in the and for with advanced breast cancer an 2 2018; Scopus Google and an for to with to regarding the of and the of in regarding of in and of in with due to the of in the et and of with in with breast cancer in Breast Full Text Full Text PDF PubMed Scopus Google Scholar]. and for been and to with in the of to the of on an with a with in the of to of the The of the on the and the The of The of for to a the of and to and years of in some in of of for ABC. for the in with for a in the and of with with for and a to has been in of and to in data to to with in the for the with with of to of in terms of and for with the of and has to to in terms of in the with the of and an for of in the and with data the of with and and a with the of to to in the of in of an data on the of with of on the a for some data on the of on the of for with a in and with the in a with and of with in in The and and to with a of and in advanced breast and of in with the of human epidermal growth factor of OS, overall in in a advanced breast and of in with the of human epidermal growth factor of OS, overall for the of and data in the 2 The to the of disease for the et of and in with metastatic breast cancer Google Scholar]. the of with in with in the metastatic the to the of and been a the for the of the publication of the et and for metastatic breast cancer overall survival a Full Text Full Text PDF PubMed Scopus Google Scholar] a a to the to in with the the has a of for a the a of for in the for the and data on both and with a to the in the of the of for with to with a with a disease in terms of receptor F. Costa A. et International Consensus Guidelines for Advanced Breast Cancer publication Google Scholar]. and and for in only in the metastatic in to a of in of the The of a of for of a and the for a in of and to in in the with an advanced data for disease for advanced advanced of with with in the and a with and an a in advanced to data a of for and in More and to and the of of in with the of human epidermal growth factor of breast in a of in with the of human epidermal growth factor of breast advances been in 2 years in the of advanced breast cancer remains the only for advanced with regarding of with the of The of breast cancer to the of for of the of an of receptor The that an for the of has to some in advanced the that of in in of the data that A. S. et of in with metastatic breast Cancer PubMed Scopus Google Scholar, et of in with receptor locally advanced metastatic breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar, et for the of breast 2018; PubMed Scopus Google Scholar] and the of the and the of in breast cancer has been on the and to for on and only in and for to the to the that a in to has for the in the of of in breast to a and for in with advanced with an with a the metastatic a the and to a for with advanced on with an a the metastatic with a improvement in and a with in and in advanced breast of in with the of of OS, overall quality of breast in a advanced breast of in with the of of OS, overall quality of breast the of in the of and S. F. et and in and cancer Guidelines for cancer and Full Text Full Text PDF PubMed Scopus Google Scholar] and for with to for on and only in and Although the for to the to the that a in to has in the of ABC. a cancer in and a in has been and the the of the and of in with breast cancer: for PubMed Scopus Google Scholar, et of in with breast cancer: a PubMed Scopus Google Scholar]. The S. et for metastatic breast cancer in with a PubMed Scopus Google Scholar] the of the in with and advanced for metastatic of in the advanced The in the in and of due to in the in the the Breast Cancer the of the et of the in with locally advanced metastatic breast cancer Google Scholar]. a to the of in with a with a median of in the in and in the and the the of the with improved an for ABC. studies to the of in with on in for on remains and in to in of and to a with in the of to for a in the the with for and for of of an in the of a and the information an with a with with an a an with a with an with a a the of data for on the and to data with with a for of in the of of in advanced breast of in with the of of receptor disease receptor in a advanced breast of in with the of of receptor disease receptor and in in the and in of a for breast that been with in and that with in for of breast on on for and studies that a to and and that to to and that a of F. F. et and to of metastatic breast cancer: a 2014; Full Text Full Text PDF PubMed Scopus Google Scholar, A. et based on for advanced cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar]. The of only to to the of receptor to that the of of a an in the of the of that to the the and the of in the to that of the that data to regarding to in the of an in for breast cancer of in the in of for in with and due to to a of a has an the of the of a the of and the of a of a of the of the the of for the of and an in with in with and to to of and with a a of with an for some in with the the of disease and the of and with and for of and to and in the of a of with with with the only of the of to to the of the disease and to the been with with the of disease a in a in for an that with survival and and in in of with of with a of the of an to the a of 2 for a median of to of for breast cancer only in data the of on of a only in of with has of the data to the for the for that in with of an of the and to the of with of and and with with of for of of the in to in the of the of in disease and in for disease and of on of and with disease to the of to for ABC. for advanced breast of in with the of human epidermal growth factor of in a advanced breast of in with the of human epidermal growth factor of the of the survival of has the and of a of for the of a with with a of the of has been in some studies L. et of for of the Full Text Full Text PDF PubMed Scopus Google Scholar, et with for PubMed Scopus Google Scholar, D. et a for of PubMed Scopus Google Scholar, L. et of with in PubMed Scopus Google Scholar, et analysis of of the with 2014; PubMed Scopus Google Scholar, D. S. F. et for the of a of the PubMed Google Scholar] with of an to the with and been a of 2 for a median of More to breast the of the the of disease a the with to an a the with of in for advanced breast of in with the of of in a for advanced breast of in with the of of a and to a of metastatic a a and of and with and of of and in to and the remains and the to in an overall improvement in based on a and in the of for an and of on and and and the of in the an with the with in and and with a the of of with in of with in the of in with a with of disease with an the for of overall to for with with in to in with and a with advanced breast of in with the of human epidermal growth factor locally advanced breast of quality of the of locally advanced breast in a advanced breast of in with the of human epidermal growth factor locally advanced breast of quality of the of locally advanced breast The of with disease with and the disease remains to of the with a to with an to an of to with a of disease and a to on the to the to of the of to that for on and L. F. et in breast cancer of a Full Text Full Text PDF PubMed Scopus Google Scholar]. of the of with a in a in with metastatic cancer and in to A. the breast cancer Full Text Full Text PDF PubMed Scopus Google Scholar]. and of of the of of and a to for in of the of life in the of metastatic to and and the of and of the with the the of with a on and and The of to to in of the with and with an in has been to of an of to of and for 2 with of and for of of in the of in the of in in an in of the to of and F. A. et and for the of and and and of and in advanced cancer Full Text Full Text PDF PubMed Scopus Google Scholar] for of and and and the a to and to of of of and of of of and to of and 2 with and in with for to 2 and and to and and for 2 and for of for of to 2 the and the of the and for the of to of and for and to the of of and the and of for with and studies to for and of of and of the of of of and of and studies to for and of advanced breast of in with the for of and of of in of a quality of in a advanced breast of in with the for of and of of in of a quality of in the the of disease and a and that a the for of been the of for of L. et of in with metastatic breast cancer a 2 Full Text Full Text PDF PubMed Scopus Google Scholar, et of and Guidelines for and Full Text Full Text PDF PubMed Scopus Google and been for of and and S. et the of for in 2018; PubMed Scopus Google Scholar, The to and of of Scholar, and of with in with in breast PubMed Scopus Google Scholar]. and an and to for a of of the to a the a and a to and The of to the of and and for to and some the the and with the and to and and the for the on on the and the that with an based on the of the regarding and of in of cancer Cancer that the of to and and that of for information in of the with the to to in the in the to disease of the of of the to of and and and and and and and some of and and with of in shows with the and advanced breast of in with the of of OS, overall quality of in a advanced breast of in with the of of OS, overall quality of and the of with in a and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar]. of based in of cancer that the and been the and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar]. The the of to cancer in in the has been to to the of with cancer the has been in of of has been to to and to The of the a of cancer that and cancer to and the cancer to to cancer and to and cancer et for Cancer Scholar]. the to disease of the of breast cancer The and of the of for and in breast cancer of the to of and and and in breast cancer a and in an improvement in and in with A. et of on and quality of life in advanced breast cancer Full Text PDF Google Scholar] and and and and some of and and and and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar, et for the and of with breast cancer: PubMed Scopus Google Scholar]. that the in shows with the and and for breast cancer based Full Text Full Text PDF PubMed Scopus Google Scholar, et for the and of with breast cancer: PubMed Scopus Google Scholar]. the of in been the and the Consensus the and the an to the

In the last decade we have witnessed a dramatic increase in the proportion and absolute number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant bacteria are currently considered as an emergent global disease and a major public health problem. The B-Debate meeting brought together renowned experts representing the main stakeholders (i.e. policy makers, public health authorities, regulatory agencies, pharmaceutical companies and the scientific community at large) to review the global threat of antibiotic resistance and come up with a coordinated set of strategies to fight antimicrobial resistance in a multifaceted approach. We summarize the views of the B-Debate participants regarding the current situation of antimicrobial resistance in animals and the food chain, within the community and the healthcare setting as well as the role of the environment and the development of novel diagnostic and therapeutic strategies, providing expert recommendations to tackle the global threat of antimicrobial resistance.

BACKGROUND: Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality. METHODS: In this randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland. Exclusion criteria were previous bilateral oophorectomy or ovarian malignancy, increased risk of familial ovarian cancer, and active non-ovarian malignancy. The trial management system confirmed eligibility and randomly allocated participants in blocks of 32 using computer-generated random numbers to annual multimodal screening (MMS) with serum CA125 interpreted with use of the risk of ovarian cancer algorithm, annual transvaginal ultrasound screening (USS), or no screening, in a 1:1:2 ratio. The primary outcome was death due to ovarian cancer by Dec 31, 2014, comparing MMS and USS separately with no screening, ascertained by an outcomes committee masked to randomisation group. All analyses were by modified intention to screen, excluding the small number of women we discovered after randomisation to have a bilateral oophorectomy, have ovarian cancer, or had exited the registry before recruitment. Investigators and participants were aware of screening type. This trial is registered with ClinicalTrials.gov, number NCT00058032. FINDINGS: Between June 1, 2001, and Oct 21, 2005, we randomly allocated 202,638 women: 50,640 (25·0%) to MMS, 50,639 (25·0%) to USS, and 101,359 (50·0%) to no screening. 202,546 (>99·9%) women were eligible for analysis: 50,624 (>99·9%) women in the MMS group, 50,623 (>99·9%) in the USS group, and 101,299 (>99·9%) in the no screening group. Screening ended on Dec 31, 2011, and included 345,570 MMS and 327,775 USS annual screening episodes. At a median follow-up of 11·1 years (IQR 10·0-12·0), we diagnosed ovarian cancer in 1282 (0·6%) women: 338 (0·7%) in the MMS group, 314 (0·6%) in the USS group, and 630 (0·6%) in the no screening group. Of these women, 148 (0·29%) women in the MMS group, 154 (0·30%) in the USS group, and 347 (0·34%) in the no screening group had died of ovarian cancer. The primary analysis using a Cox proportional hazards model gave a mortality reduction over years 0-14 of 15% (95% CI -3 to 30; p=0·10) with MMS and 11% (-7 to 27; p=0·21) with USS. The Royston-Parmar flexible parametric model showed that in the MMS group, this mortality effect was made up of 8% (-20 to 31) in years 0-7 and 23% (1-46) in years 7-14, and in the USS group, of 2% (-27 to 26) in years 0-7 and 21% (-2 to 42) in years 7-14. A prespecified analysis of death from ovarian cancer of MMS versus no screening with exclusion of prevalent cases showed significantly different death rates (p=0·021), with an overall average mortality reduction of 20% (-2 to 40) and a reduction of 8% (-27 to 43) in years 0-7 and 28% (-3 to 49) in years 7-14 in favour of MMS. INTERPRETATION: Although the mortality reduction was not significant in the primary analysis, we noted a significant mortality reduction with MMS when prevalent cases were excluded. We noted encouraging evidence of a mortality reduction in years 7-14, but further follow-up is needed before firm conclusions can be reached on the efficacy and cost-effectiveness of ovarian cancer screening. FUNDING: Medical Research Council, Cancer Research UK, Department of Health, The Eve Appeal.

BACKGROUND: The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships. METHODS: The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods. FINDINGS: Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up). INTERPRETATION: Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV. FUNDING: National Institute for Health Research.

We describe a theoretical model of the neurocognitive mechanisms underlying conscious presence and its disturbances. The model is based on interoceptive prediction error and is informed by predictive models of agency, general models of hierarchical predictive coding and dopaminergic signaling in cortex, the role of the anterior insular cortex (AIC) in interoception and emotion, and cognitive neuroscience evidence from studies of virtual reality and of psychiatric disorders of presence, specifically depersonalization/derealization disorder. The model associates presence with successful suppression by top-down predictions of informative interoceptive signals evoked by autonomic control signals and, indirectly, by visceral responses to afferent sensory signals. The model connects presence to agency by allowing that predicted interoceptive signals will depend on whether afferent sensory signals are determined, by a parallel predictive-coding mechanism, to be self-generated or externally caused. Anatomically, we identify the AIC as the likely locus of key neural comparator mechanisms. Our model integrates a broad range of previously disparate evidence, makes predictions for conjoint manipulations of agency and presence, offers a new view of emotion as interoceptive inference, and represents a step toward a mechanistic account of a fundamental phenomenological property of consciousness.

That mortality in developed countries is affected more by relative than absolute living standards is shown by three pieces of evidence. Firstly, mortality is related more closely to relative income within countries than to differences in absolute income between them. Secondly, national mortality rates tend to be lowest in countries that have smaller income differences and thus have lower levels of relative deprivation. Thirdly, most of the long term rise in life expectancy seems unrelated to long term economic growth rates. Although both material and social influences contribute to inequalities in health, the importance of relative standards implies that psychosocial pathways may be particularly influential. During the 1980s income differences widened more rapidly in Britain than in other countries; almost a quarter of the population now lives in relative poverty. The effects of higher levels of relative deprivation and lower social cohesion may already be visible in mortality trends among young adults. A “feel bad” factor in the health divide? TONY WALLIS The existence of wide-and widening-socioeconomic differences in health shows how extraordinarily sensitive health remains to socioeconomic circumstances. Twofold, threefold, or even fourfold differences in mortality have been reported within Britain, depending largely on the social classification used.1 2 3 This series will illustrate some of the most important mechanisms involved in the generation of these differences. Fundamental to understanding the causes of these differences in health is the distinction between the effects of relative and absolute living standards. Socioeconomic gradients in health are simultaneously an association with social position and with different material circumstances, both of which have implications for health-but which is more important in terms of causality? Is the health disadvantage of the least well off part of the population mainly a reflection of the direct physiological effects of lower absolute material standards (of bad …

SIGNIFICANCE: Oxidative stress is considered to be an important component of various diseases. A vast number of methods have been developed and used in virtually all diseases to measure the extent and nature of oxidative stress, ranging from oxidation of DNA to proteins, lipids, and free amino acids. RECENT ADVANCES: An increased understanding of the biology behind diseases and redox biology has led to more specific and sensitive tools to measure oxidative stress markers, which are very diverse and sometimes very low in abundance. CRITICAL ISSUES: The literature is very heterogeneous. It is often difficult to draw general conclusions on the significance of oxidative stress biomarkers, as only in a limited proportion of diseases have a range of different biomarkers been used, and different biomarkers have been used to study different diseases. In addition, biomarkers are often measured using nonspecific methods, while specific methodologies are often too sophisticated or laborious for routine clinical use. FUTURE DIRECTIONS: Several markers of oxidative stress still represent a viable biomarker opportunity for clinical use. However, positive findings with currently used biomarkers still need to be validated in larger sample sizes and compared with current clinical standards to establish them as clinical diagnostics. It is important to realize that oxidative stress is a nuanced phenomenon that is difficult to characterize, and one biomarker is not necessarily better than others. The vast diversity in oxidative stress between diseases and conditions has to be taken into account when selecting the most appropriate biomarker.

Influential theories suggest emotional feeling states arise from physiological changes from within the body. Interoception describes the afferent signalling, central processing, and neural and mental representation of internal bodily signals. Recent progress is made in conceptualizing interoception and its neural underpinnings. These developments are supported by empirical data concerning interoceptive mechanisms and their contribution to emotion. Fresh insights include description of short-term interoceptive effects on neural and mental processes (including fear-specific cardiac effects), the recognition of dissociable psychological dimensions of interoception, and models of interoceptive predictive coding that explain emotions and selfhood (reinforced by structural anatomical models and brain and experimental findings). This growing grasp of interoception is enriching our understanding of emotion and its disorders.

BACKGROUND: Tumor spatial heterogeneity is an important prognostic factor, which may be reflected in medical images METHODS: Image texture analysis is an approach of quantifying heterogeneity that may not be appreciated by the naked eye. Different methods can be applied including statistical-, model-, and transform-based methods. RESULTS: Early evidence suggests that texture analysis has the potential to augment diagnosis and characterization as well as improve tumor staging and therapy response assessment in oncological practice. CONCLUSION: This review provides an overview of the application of texture analysis with different imaging modalities, CT, MRI, and PET, to date and describes the technical challenges that have limited its widespread clinical implementation so far. With further efforts to refine its application, image texture analysis has the potential to develop into a valuable clinical tool for oncologic imaging. TEACHING POINTS : • Tumor spatial heterogeneity is an important prognostic factor. • Image texture analysis is an approach of quantifying heterogeneity. • Different methods can be applied, including statistical-, model-, and transform-based methods. • Texture analysis could improve the diagnosis, tumor staging, and therapy response assessment.

BACKGROUND: Ovarian cancer has a high case-fatality ratio, with most women not diagnosed until the disease is in its advanced stages. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a randomised controlled trial designed to assess the effect of screening on mortality. This report summarises the outcome of the prevalence (initial) screen in UKCTOCS. METHODS: Between 2001 and 2005, a total of 202 638 post-menopausal women aged 50-74 years were randomly assigned to no treatment (control; n=101 359); annual CA125 screening (interpreted using a risk of ovarian cancer algorithm) with transvaginal ultrasound scan as a second-line test (multimodal screening [MMS]; n=50 640); or annual screening with transvaginal ultrasound (USS; n=50 639) alone in a 2:1:1 ratio using a computer-generated random number algorithm. All women provided a blood sample at recruitment. Women randomised to the MMS group had their blood tested for CA125 and those randomised to the USS group were sent an appointment to attend for a transvaginal scan. Women with abnormal screens had repeat tests. Women with persistent abnormality on repeat screens underwent clinical evaluation and, where appropriate, surgery. This trial is registered as ISRCTN22488978 and with ClinicalTrials.gov, number NCT00058032. FINDINGS: In the prevalence screen, 50 078 (98.9%) women underwent MMS, and 48 230 (95.2%) underwent USS. The main reasons for withdrawal were death (two MMS, 28 USS), non-ovarian cancer or other disease (none MMS, 66 USS), removal of ovaries (five MMS, 29 USS), relocation (none MMS, 39 USS), failure to attend three appointments for the screen (72 MMS, 757 USS), and participant changing their mind (483 MMS, 1490 USS). Overall, 4355 of 50 078 (8.7%) women in the MMS group and 5779 of 48 230 (12.0%) women in the USS group required a repeat test, and 167 (0.3%) women in the MMS group and 1894 (3.9%) women in the USS group required clinical evaluation. 97 of 50 078 (0.2%) women from the MMS group and 845 of 48 230 (1.8%) from the USS group underwent surgery. 42 (MMS) and 45 (USS) primary ovarian and tubal cancers were detected, including 28 borderline tumours (eight MMS, 20 USS). 28 (16 MMS, 12 USS) of 58 (48.3%; 95% CI 35.0-61.8) of the invasive cancers were stage I/II, with no difference (p=0.396) in stage distribution between the groups. A further 13 (five MMS, eight USS) women developed primary ovarian cancer during the year after the screen. The sensitivity, specificity, and positive-predictive values for all primary ovarian and tubal cancers were 89.4%, 99.8%, and 43.3% for MMS, and 84.9%, 98.2%, and 5.3% for USS, respectively. For primary invasive epithelial ovarian and tubal cancers, the sensitivity, specificity, and positive-predictive values were 89.5%, 99.8%, and 35.1% for MMS, and 75.0%, 98.2%, and 2.8% for USS, respectively. There was a significant difference in specificity (p<0.0001) but not sensitivity between the two screening groups for both primary ovarian and tubal cancers as well as primary epithelial invasive ovarian and tubal cancers. INTERPRETATION: The sensitivity of the MMS and USS screening strategies is encouraging. Specificity was higher in the MMS than in the USS group, resulting in lower rates of repeat testing and surgery. This in part reflects the high prevalence of benign adnexal abnormalities and the more frequent detection of borderline tumours in the USS group. The prevalence screen has established that the screening strategies are feasible. The results of ongoing screening are awaited so that the effect of screening on mortality can be determined.

Summary points: Economic and social circumstances affect health through the physiological effects of their emotional and social meanings and the direct effects of material circumstances. Material conditions do not adequately explain health inequalities in rich countries. The relation between smaller inequalities in income and better population health reflects increased psychosocial wellbeing. In rich countries wellbeing is more closely related to relative income than absolute income. Social dominance, inequality, autonomy, and the quality of social relations have an impact on psychosocial wellbeing and are among the most powerful explanations for the pattern of population health in rich countries.